Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Jun 7

PMID 34094973

Citations 5

Authors

Nicolas Epaillard

Pauline Parent

Yohann Loriot

Pernelle Lavaud

E-B Vera-Cea

Nieves Martinez-Chanza

Alejo Rodriguez-Vida

Clement Dumont

Rebeca Lozano

Casilda Llacer

Raffaele Ratta

Stephane Oudard

Constance Thibault

Edouard Auclin

Affiliations

Soon will be listed here.

Abstract

Introduction: Less than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate the efficacy of systemic treatments in VH or non-UC bladder cancers.

Materials: Multicenter retrospective analysis of patients treated for advanced or metastatic VH or non-UC bladder cancers. Primary endpoint was overall response rate (ORR) according to treatment line, regimen and histology subtype. Secondary endpoints were progression-free survival (PFS) and overall survival (OS).

Results: Between 2005 and 2020, 46 patients from seven centers were included. The median age was 66 years (58.75; 74.75), 65.2% were male and 67.2% presented VH. At first line, the ORR for the entire population was 54.4% and median OS was 21.6 months (95% confidence interval [CI]: 14.2-38.6). The ORR of the 37 patients treated with chemotherapy at first line was 62.2% with median PFS and OS of 7.3 (95% CI: 4.5-8.6) and 21.6 months (95% CI: 14.2-35.7), respectively. Dose dense MVAC and platinum doublet chemotherapy had the highest ORR (71.4% and 65.2%). The 9 patients treated with immunotherapy at first line had an ORR of 22.2%, a median PFS of 3.3 months (95% CI:2.3-NR) and the median OS was not reached (95% CI:13.8-NR). Response to treatment varied depending on the histological sub-types and on the treatment type.

Conclusion: Chemotherapy and immunotherapy have shown to be effective in VH or non-UC cancers, a rare histological subtype for which we currently have very little data in the literature.

Citing Articles

Clinicopathological features and treatment outcomes of urothelial carcinoma variant histologies and non-urothelial bladder cancers.

Seven I, Akturk Esen S, Sekmek S, Karahan I, Buyukaksoy M, Unal T Int Urol Nephrol. 2024; .

PMID: 39729262 DOI: 10.1007/s11255-024-04341-w.

Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology.

Minato A, Murooka K, Okumura Y, Takaba T, Higashijima K, Nagata Y In Vivo. 2024; 38(2):873-880.

PMID: 38418119 PMC: 10905432. DOI: 10.21873/invivo.13513.

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer.

Parent P, Marcq G, Adeleke S, Turpin A, Boussios S, Rassy E Ther Adv Med Oncol. 2023; 15:17588359231192402.

PMID: 37692364 PMC: 10486227. DOI: 10.1177/17588359231192402.

Neoadjuvant chemotherapy for muscle-invasive bladder cancer: does variant histology matter?.

Catarino R, Alves L, Pereira D, Costa G, Pereira J, Cardoso A Int Urol Nephrol. 2022; 54(12):3163-3169.

PMID: 36063276 DOI: 10.1007/s11255-022-03358-3.

Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review.

Barone B, Calogero A, Scafuri L, Ferro M, Lucarelli G, Di Zazzo E Cancers (Basel). 2022; 14(10).

PMID: 35626149 PMC: 9139497. DOI: 10.3390/cancers14102545.

References

Powles T, van der Heijden M, Castellano D, Galsky M, Loriot Y, Petrylak D . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020; 21(12):1574-1588. DOI: 10.1016/S1470-2045(20)30541-6. View

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

Griffiths G, Cowan R, Grigor K, Uscinska B, Sydes M, Russell M . BA08: An open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract. PLoS One. 2019; 14(1):e0210785. PMC: 6334943. DOI: 10.1371/journal.pone.0210785. View

Lobo N, Shariat S, Guo C, Fernandez M, Kassouf W, Choudhury A . What Is the Significance of Variant Histology in Urothelial Carcinoma?. Eur Urol Focus. 2019; 6(4):653-663. DOI: 10.1016/j.euf.2019.09.003. View

Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A . Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007; 52(1):134-41. DOI: 10.1016/j.eururo.2006.12.029. View

Buisan O, Orsola A, Oliveira M, Martinez R, Etxaniz O, Areal J . Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy. Clin Genitourin Cancer. 2017; 15(4):e697-e706. DOI: 10.1016/j.clgc.2017.01.024. View

Yu B, Zhou J, Cai H, Xu T, Xu Z, Zou Q . Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience. BMC Urol. 2015; 15:3. PMC: 4328949. DOI: 10.1186/1471-2490-15-3. View

Martin J, Carballido E, Ahmed A, Farhan B, Dutta R, Smith C . Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches. Arab J Urol. 2016; 14(3):183-91. PMC: 4983161. DOI: 10.1016/j.aju.2016.07.001. View

Choong N, Quevedo J, Kaur J . Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005; 103(6):1172-8. DOI: 10.1002/cncr.20903. View

10.

Sternberg C, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F . Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. Eur Urol. 2019; 76(1):73-81. DOI: 10.1016/j.eururo.2019.03.015. View

11.

Shah R, Montgomery J, Montie J, Kunju L . Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol. 2012; 31(8):1650-5. DOI: 10.1016/j.urolonc.2012.04.009. View

12.

Zargar-Shoshtari K, Sverrisson E, Sharma P, Gupta S, Poch M, Pow-Sang J . Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. Clin Genitourin Cancer. 2015; 14(1):82-8. DOI: 10.1016/j.clgc.2015.08.006. View

13.

Mukesh M, Cook N, Hollingdale A, Ainsworth N, Russell S . Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network. BJU Int. 2008; 103(6):747-52. DOI: 10.1111/j.1464-410X.2008.08241.x. View

14.

Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R . Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018; 36(34):3353-3360. DOI: 10.1200/JCO.18.01148. View

15.

Galsky M, Iasonos A, Mironov S, Scattergood J, Donat S, Bochner B . Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007; 69(2):255-9. DOI: 10.1016/j.urology.2006.10.029. View

16.

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18(3):312-322. DOI: 10.1016/S1470-2045(17)30065-7. View

17.

Kim M, Umemura Y, Leung D . Bevacizumab and Glioblastoma: Past, Present, and Future Directions. Cancer J. 2018; 24(4):180-186. DOI: 10.1097/PPO.0000000000000326. View

18.

Sternberg C, De Mulder P, Schornagel J, Theodore C, Fossa S, Van Oosterom A . Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2005; 42(1):50-4. DOI: 10.1016/j.ejca.2005.08.032. View

19.

Clark P . Urothelial carcinoma with squamous differentiation: response to chemotherapy and radiation. Urol Oncol. 2015; 33(10):434-6. DOI: 10.1016/j.urolonc.2015.06.019. View

20.

Lopez-Beltran A, Henriques V, Montironi R, Cimadamore A, Raspollini M, Cheng L . Variants and new entities of bladder cancer. Histopathology. 2018; 74(1):77-96. DOI: 10.1111/his.13752. View